Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of HN2301 in Patients With Refractory Myasthenia Gravis (MG)

NCT06965309 is registered in ClinicalTrials.gov with Shenzhen MagicRNA Biotechnology Co., Ltd as lead sponsor.

NCT NCT06965309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06965309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of HN2301 in Patients With Refractory Myasthenia Gravis (MG)
Lead sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase
Not applicable
Overall status
Terminated
Start date
January 19, 2026
Completion date
February 11, 2026
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory myasthenia gravis